OncLive Staff

Articles

Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine

February 8th 2024

Drs Jacob, Van Der Wall, and Wright-Browne discuss challenges and growth opportunities they have experienced throughout their careers.

Lunning and Brander Emphasize the Importance of Early CLL Diagnosis and Treatment

February 5th 2024

Drs Lunning and Brander discuss the evolution of chronic lymphocytic leukemia management.

Camidge and Okuyama Sasaki Highlight How Safety Net Hospitals Widen the Scope of Cancer Care

February 1st 2024

Drs Camidge and Okuyama Sasaki discuss the goals of safety net hospitals and the dynamics of helping low-income patients access cancer treatments.

Expert and Patient Perspectives on AE Management With FGFR Inhibitors in Cholangiocarcinoma

January 29th 2024

Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related adverse effects.

FDA Approval Insights: Pirtobrutunib in Previously Treated CLL/SLL

January 25th 2024

Dr Davids discusses the FDA approval of pirtobrutinib for patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Lunning and Maddocks Talk Through Frontline MCL Management

January 22nd 2024

Drs Lunning and Maddocks discuss the management of MCL in the up-front setting.

Camidge and Leland Discuss the Road to a Multifaceted Biotechnology Career

January 18th 2024

Drs Camidge and Leland discuss various roles in the biotechnology field and the intricacies of starting a biotechnology company.

FDA Approval Insights: Nirogacestat in Progressing Desmoid Tumors Requiring Systemic Treatment

January 15th 2024

Dr Kasper discusses the FDA approval of nirogacestat for patients with progressing desmoid tumors; key efficacy, safety, and quality-of-life outcomes from the pivotal DeFi trial; and findings from an analysis investigating tumor volume and T2 hyperintensity changes with nirogacestat in patients enrolled in DeFi.

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024

Drs Monk and Tarantino highlight current research investigating B7-H4–directed antibody-drug conjugates. in multiple solid tumor types.

Donington and Stiles Summarize NSCLC Resectability Parameters and Multidisciplinary Management

January 8th 2024

Drs Donington and Stiles discuss the implications of perioperative immunotherapy trials on early-stage lung cancer management, definitions of resectability, and the incorporation of new multidisciplinary management guidance.

FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

January 4th 2024

Dr Gradishar discusses the FDA approval of capivasertib plus fulvestrant for patients with advanced HR-positive, HER2-negative breast cancer harboring PIK3CA, AKT1, or PTEN alterations.

Santos Summarizes Key Updates From EMPOWER-Lung 1 and EMPOWER-Lung 3 With Cemiplimab in NSCLC

January 1st 2024

Dr Santos discusses findings from the EMPOWER-Lung 3 trial of cemiplimab plus chemotherapy in patients with advanced non–small cell lung cancer, as well as data from subgroup analyses of the EMPOWER-Lung 1 trial of cemiplimab monotherapy in patients with NSCLC and a PD-L1 score over 50%.

OncLive December Recap: FDA Approval Highlights

December 30th 2023

In case you missed it, below are some of the drugs that were approved by the FDA in the month of December.

Jabbour Reports Top Takeaways From ASH 2023 of Olverembatinib in CML and ALL

December 28th 2023

Dr Jabbour discusses the activity and the utilization of olverembatinib in chronic myeloid leukemia and expanded upon the role that TKIs can play in the management of malignancies beyond chronic myeloid leukemia and acute lymphoblastic leukemia.

Eskander Emphasizes the Importance of Inclusivity and Accessibility in Oncology Clinical Trials

December 25th 2023

Dr Eskander discusses the impact of social determinants of health on cancer clinical trial participation; effective strategies for considering and engaging diverse communities in the clinical trial process; and how community partnerships can be strengthened to eliminate these financial and logistical barriers.

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

December 21st 2023

Drs Lunning and Mehta-Shah highlight challenges that arise when diagnosing patients with peripheral T-cell lymphoma and how molecular testing results influence induction and consolidation treatment approaches for patients with ALK-negative anaplastic large cell lymphoma.

Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors

December 18th 2023

Drs Simeone and Fakih discuss the main objective and design of the observational BASECAMP-1 study and how it functions alongside the EVEREST-1 study, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with CEA-expressing solid tumors that have lost HLA-A*02 expression.

Camidge and Gerber Emphasize the Importance of Face-to-Face Patient Connections

December 14th 2023

Drs Camidge and Gerber highlight the ways that a liberal arts education can lay the foundation for a successful career in academic medicine; the importance and various forms of mentorship; and how clinical investigators can use their experiences and data to drive national policy changes.

Donington and Stiles Describe the Surgical Implications of Lung Cancer Treatment Evolutions

December 11th 2023

Drs Donington and Stiles discuss how the findings from the ADAURA trial with adjuvant osimertinib have changed thoracic surgery expectations, the potential surgical implications of the ALINA trial with adjuvant alectinib, and the importance of early-stage molecular testing in lung cancer.

Abdou Spotlights Factors Influencing ADC Treatment Selection in Breast Cancer

December 7th 2023

Dr Abdou discusses how characteristics of patients with breast cancer impact ADC treatment selection and highlights some of the topline takeaways from breast cancer treatment to come out of the 2023 ASCO Annual Meeting.